FDPS antibody (AA 389-419)

Catalog No. ABIN389054

Product Details anti-FDPS Antibody

Target: FDPS (Farnesyl Diphosphate Synthase (FDPS))

Binding Specificity: AA 389-419

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FDPS antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This FDPS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 389-419 amino acids from the center region of human FDPS.

Clone: RB04786

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:10~50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-FDPS antibody (ABIN389054)

Sousa, Auriola, Mönkkönen, Määttä: "Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells." in: BMC cancer, Vol. 15, pp. 4, (2015) (PubMed).

Todenhöfer, Hennenlotter, Kühs, Gerber, Gakis, Vogel, Aufderklamm, Merseburger, Knapp, Stenzl, Schwentner: "Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?" in: World journal of urology, Vol. 31, Issue 2, pp. 345-50, (2013) (PubMed).

Zhang, Dai, Wang: "5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis." in: Molecular & cellular proteomics : MCP, Vol. 11, Issue 7, pp. M111.016915, (2012) (PubMed).

Ishimoto, Tachibana, Hanano, Yamasaki, Nakamura, Kawai, Urano, Tanaka, Hamakubo, Sakai, Kodama, Doi: "Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells." in: The Biochemical journal, Vol. 429, Issue 2, pp. 347-57, (2010) (PubMed).

Räikkönen, Mönkkönen, Auriola, Mönkkönen: "Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells." in: Biochemical pharmacology, Vol. 79, Issue 5, pp. 777-83, (2010) (PubMed).

Li, Herold, Kimmel, Müller, Rincon-Orozco, Kunzmann, Herrmann: "Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 12, pp. 8118-24, (2009) (PubMed).

Target Details for FDPS

Target: FDPS (Farnesyl Diphosphate Synthase (FDPS))

Alternative Name: FDPS (FDPS Products)

Background: The isoprene biosynthetic pathway supply the cell with cholesterol, ubiquinone, and various nonsterol metabolites. The farnesylpyrophosphate synthetase enzyme catalyzes the formation of geranyl and farnesylpyrophosphate from isopentenylpyrophosphate and dimethylallyl pyrophosphate. Analysis of FDPS activity and protein in rat liver, accompanied by immunofluorescence and immunoelectron microscopy studies, demonstrated that FDPS is predominantly localized in peroxisomes.1 Liver tissue from patients with the peroxisomal deficiency diseases Zellweger syndrome and neonatal adrenoleukodystrophy exhibit diminished activities of FDPS and subsequent isoprenoid synthesis.

Molecular Weight: 48275

Gene ID: 2224

NCBI Accession: NP_001129293, NP_001129294, NP_001229753, NP_001229754, NP_001995

UniProt: P14324

Pathways: Regulation of Muscle Cell Differentiation